EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Funded Projects
Based on current funded research
Updated May 3, 2023
Data provided by University at Buffalo Sponsored Projects Services
| Award Principal Investigator | Award Name | Award Type | Sponsor Name | Award Start Date | Award End Date | Total Cost |
|---|---|---|---|---|---|---|
| Balthasar, Dr. Joseph | Center for Protein Therapeutics | Nonfederal | Multiple Sponsors | 1-Sep-17 | 31-Aug-23 | 9,674,501.70 |
| Balthasar, Dr. Joseph | Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors | Federal | National Cancer Institute | 1-Jun-20 | 31-May-25 | 1,807,227.00 |
| Balthasar, Dr. Joseph | Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization | Federal | National Cancer Institute | 1-Jun-21 | 31-May-26 | 1,817,098.00 |
| Balthasar, Dr. Joseph | SBIR A1: Lead Optimization and Evaluation of Anti-SN38 Payload Binding Selectivity Enhancers | Federal | Abceutics | 15-Sep-21 | 31-Aug-23 | 55,000.00 |
| Balthasar, Dr. Joseph | Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia | Federal | National Cancer Institute | 1-Feb-23 | 31-Jan-28 | 2,137,191.00 |
| Balthasar, Dr. Joseph | Improving antibody distribution with transient antigen binding inhibition | Nonfederal | Empire Discover Institute | 08-Dec-22 | 07-Dec-23 | 180,000.00 |
| Balu-Iyer, Dr. Sathy V. | Lipid mediated oral tolerance | Federal | National Institute of Allergy & Infectious Disease | 16-Jun-22 | 31-May-27 | 2,327,530.00 |
| Balu-Iyer, Dr. Sathy V. | Development of tolerogenic Factor VIII as immunotherapy to prevent inhibitor development in Hemophilia A | Federal | National Heart Lung and Blood Institute | 27-Mar-23 | 28-Feb-25 | 1,132,306.00 |
| Bednarczyk, Dr. Edward M. | C19: Chronic Disease Medication Utilization and the Novel Coronavirus Disease 2019 (COVID-19) Infection | Nonfederal | American College of Clinical Pharmacy | 01-Jan-21 | 31-Jul-23 | 600.00 |
| Bednarczyk, Dr. Edward M. | NYS Prescription Monitoring CE Program | Federal Flow Through | Island Peer Review Organization | 1-Sep-21 | 31-Dec-23 | 188,394.00 |
| Bednarczyk, Dr. Edward M. | Opioid Prescriber Training Program | Federal Flow Through | Health Research Inc. | 1-Sep-2022 | 31-Aug-2023 | 70,000.00 |
| Bies, Dr. Robert R. | Physiologically-based model of the female reproductive tract: vaginal and intrauterine delivery components- Support New Approaches to Improve Product Manufacturing and Quality | Federal | US Food and Drug Administration | 26-Sep-18 | 25-Jan-24 | 940,749.00 |
| Bies, Dr. Robert R. | Pharmacokinetics of sedatives - Understanding a modifiable risk factor for pediatric delirium | Federal Flow Through | Childrens Research Institute | 1-Sep-19 | 31-Jul-24 | 77,492.00 |
| Bies, Dr. Robert R. | Long Acting Film Technology for Contraception and HIV Prevention (LATCH) | Federal Flow Through | Magee-Womens Research Institute and Foundation | 1-Feb-21 | 31-Jan-24 | 219,856.00 |
| Bies, Dr. Robert R. | Evaluation of safety and pharmacokinetics of naltrexone implant | Federal Flow Through | Research Foundation for Mental Hygiene | 1-Mar-21 | 31-Aug-23 | 180,584.00 |
| Bies, Dr. Robert R. | The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC) | Federal Flow Through | Trustees of Indiana University | 10-Sep-2021 | 31-Jul-26 | 1,913,969.00 |
| Bies, Dr. Robert R. | Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence, MATRIX | Federal Flow Through | Magee-Womens Research Institute and Foundation | 01-Dec-2021 | 31-Dec-26 | 1,201,995.00 |
| Bies, Dr. Robert R | Population Pharmacokinetic Modeling and Clinical Trial Simulation to optimize HIV Prevention in Pregnancy and Postpartum | Federal Flow Through | Medstar Health Research Institute | 01-Aug-22 | 31-Jul-23 | 115,776.00 |
| Cha, Dr. Raymond | FELLOWSHIP for Melissa Stein (AFPE Gateway to Research) | Nonfederal | American Foundation Pharmaceutical Education | 01-Jul-22 | 30-Jun-23 | 5,000.00 |
| Clark, Dr. Collin M. | A Pilot Pharmacist-to-Pharmacist Hand-off Intervention During Transitions of Care | Nonfederal | American Association of Colleges of Pharmacy | 01-Mar-23 | 28-Feb-24 | 7,500.00 |
| Daly, Dr. Christopher | Effectiveness of a Social Determinants of Health Pharmacy Program Implemented in Community Pharmacies | Federal Flow Through | Island Peer Review Organization | 01-Aug-22 | 07-Nov-24 | 68,254.00 |
| Daly, Dr. Christopher | Scaling Payer and Community Pharmacy Partnerships for Patient Care | Nonfederal | Community Pharmacy Foundation | 01-Feb-23 | 31-Oct-23 | 21,250.00 |
| Jacobs, Dr. David Matthew | Integrative Informatics Approach to Predict Readmissions and Improve Outcomes in COPD | Federal | National Heart Lung and Blood Institute | 1-Apr-21 | 31-Mar-26 | 962,055.00 |
| Jusko, Dr. William J. | Mechanistic Pharmacokinetics and Pharmacodynamics | Federal | National Institute of General Medical Sciences | 1-May-19 | 30-Apr-24 | 2,891,677.00 |
| Jusko, Dr. William J. | Training Program in Pharmacokinetics and Pharmacodynamics | Nonfederal | GlaxoSmithKline | 3-Feb-21 | 30-May-25 | 512,400.00 |
| Ma, Dr. Qing | Doravirine Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals | Nonfederal | Merck Sharp and Dohme Limited Liability Corporation | 04-Jun-19 | 30-Jun-23 | 167,705.69 |
| Ma, Dr. Qing | Aging, Polypharmacy and Neurotoxicity in Adults Living with HIV | Federal | National Institute on Aging | 1-May-20 | 28-Feb-25 | 4,006,139.00 |
| Ma, Dr. Qing | Bictegravir in the Elderly Living with HIV: Impact of Polypharmacy and Multimorbidity | Nonfederal | Gilead Sciences Incorporated | 1-Oct-19 | 30-Sep-23 | 155,175.00 |
| Mager, Dr. Donald E. | Immunologic and Neurodevelopmental Consequences of Neonatal Anemia and Thrombocytopenia and their Treatments | Federal Flow Through | Childrens Hospital of Boston | 1-Sep-18 | 30-Jun-23 | 655,057.00 |
| Mager, Dr. Donald E. | Optimizing GVHD Prevention with Systems Pharmacology Models | Federal Flow Through | Beckman Research Institute of the City of Hope | 1-Jun-19 | 31-May-24 | 571,770.00 |
| Mager, Dr. Donald E. | Genetic and Epigenetic Vulnerabilities in Prostate Cancer of African American Men | Federal Flow Through | Health Research Inc. | 1-Aug-21 | 31-Jul-23 | 112,653.00 |
| Morse, Dr. Gene | ACTG Precautionary and Prohibited Medications Database | Federal Flow Through | Regents of the University of California Los Angeles | 1-Dec-20 | 30-Nov-23 | 570,000.00 |
| Morse, Dr. Gene | University of Rochester HIV/AIDS Clinical Trial Unit - AWD00003932 | Federal Flow Through | University of Rochester | 01-Dec-2020 | 30-Nov-27 | 126,559.00 |
| Morse, Dr. Gene | HIV Clinical Pharmacology & Therapeutics Research Training Program | Federal | Fogarty International Center | 1-Mar-22 | 31-Jan-27 | 1,507,744.94 |
| Morse, Dr. Gene | Clinical Pharmacology Quality Assurance (CPQA) | Federal | National Institute of Allergy & Infectious Disease | 30-May-22 | 29-May-29 | 13,062,971.00 |
| Morse, Dr. Gene | LC-MS/MS Assay Development and Validation for CBD and CBD hydroxy metabolite | Nonfederal | Ananda Scientific | 26-Apr-22 | 25-Jul-23 | 62,441.00 |
| Morse, Dr. Gene | CENTER FOR INTEGRATED GLOBAL BIOMEDICAL SCIENCES | Nonfederal | Abbott Laboratories | 23-Nov-22 | 31-Aug-23 | 174,900.00 |
| Morse, Dr. Gene | Global Infectious Diseases Research Training Program | Federal | Fogarty International Center | 01-Mar-23 | 31-Dec-27 | 1,486,170.00 |
| Qu, Dr. Jun | The Network Biology of Pathogen-Host Interactions Driving Exacerbation in Chronic Obstructive Pulmonary Disease (COPD) | Federal | Buffalo Institute for Medical Research | 15-Sep-19 | 14-Sep-23 | 335,351.00 |
| Qu, Dr. Jun | Highly sensitive multiplexed targeted mass spectrometric assays of proteins/peptides of significance in obesity research | Federal Flow Through | Pacific Northwest National Laboratory | 19-Feb-20 | 31-Jul-23 | 618,520.00 |
| Qu, Dr. Jun | Extracellular Vesicle treatment and age-related neuropathology in non-human primates | Federal Flow Through | Trustees of Boston University | 15-Sep-20 | 30-Apr-25 | 214,634.00 |
| Qu, Dr. Jun | Role of Type 2 Immune Response in Pancreatic Cancer Tumorgenisis | Federal Flow Through | Health Research Inc. | 15-Jul-21 | 30-Jun-23 | 19,687.00 |
| Qu, Dr. Jun | GMPS-GMPR axis melanoma progression and therapy | Federal Flow Through | Duke University | 01-Aug-22 | 31-Jul-23 | 31.304.00 |
| Qu, Dr. Jun | Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression | Federal Flow Through | Health Research Inc. | 05-Aug-22 | 31-Jul-23 | 7,368.00 |
| Qu, Dr. Jun | Neuroinflammation-related phosphoprotein signaling pathways as potential therapeutic targets for GWI using an established animal model | Federal Flow Through | Virginia Commonwealth University | 1-Feb-23 | 31-Jan-24 | 39,103.00 |
| Qu, Dr. Jun | Mitochondrial Defects in the Retinal Pigment Epithelium and the CFH Risk Allele for Age-related Macular Degeneration | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 30-Jun-26 | 257,000.00 |
| Qu, Dr. Jun | Deciphering the Mechanisms Associated with High-risk AMD genotypes for ARMS2/HTRA1 and Complement Factor H | Federal Flow Through | Doheny Eye Institute | 30-Sep-22 | 31-Aug-25 | 191,400.00 |
| Qu, Dr. Jun | Mechanisms underlying extracellular vesicle mediated changes in inflammation, neural circuitry and plasticity following cortical injury in aged monkeys | Federal Flow Through | Trustees of Boston University | 15-Jul-22 | 30-Jun-27 | 319,000.00 |
| Ramanathan, Dr. Murali | The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression | Federal | US Army Medical Research Acquisition Activity | 1-Jul-20 | 30-Jun-23 | 957,000.00 |
| Shah, Dr. Dhavalkumar | Development of organ-specific quantitative systems toxicology models for antibody-drug conjugates | Nonfederal | AstraZeneca Pharmaceuticals LP | 1-Apr-22 | 09-Oct-25 | 465,771.00 |
| Sprowl, Dr. Jason Arthur | Regulation of hepatic uptake transporters by tyrosine kinases | Federal | National Institute of General Medical Sciences | 15-Sep-2021 | 31-Aug-26 | 2,321,588.00 |
| Sprowl, Dr. Jason Arthur | Role of MCT6 in mediating cisplatin-induced ototoxicity | Federal | National Inst on Deafness & Other Comm Disorders | 01-Apr-23 | 31-Mar-25 | 432,182.00 |
| Straubinger, Dr. Robert M. | Large-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy development | Federal | National Cancer Institute | 21-Dec-18 | 31-May-23 | 398,683.00 |
| Tornatore, Dr. Kathleen M. | Age and Race Influences on Immunosuppression after Renal Transplant | Federal | National Institute on Aging | 15-Aug-18 | 30-Jun-24 | 3,507,814.00 |
| Tsuji, Dr. Brian T. | Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | Federal | National Institute of Allergy & Infectious Disease | 20-Dec-19 | 30-Nov-24 | 3,920,362.00 |
| Tsuji, Dr. Brian T. | Exploitation of multiple heteroresistance for effective antibiotic combination therapy | Federal Flow Through | Emory University | 1-Jul-20 | 30-Jun-23 | 304,248.00 |
| Tsuji, Dr. Brian T. | Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa | Federal | National Institute of Allergy & Infectious Disease | 24-May-22 | 30-Apr-27 | 3,850,992.00 |
| Woo, Dr. Sukyung | Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition | Federal | National Cancer Institute | 01-Dec-2021 | 30-Nov-26 | 2,010,125.00 |
| Woo, Dr. Sukyung | Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold | Federal Flow Through | Board of Regents of the University of Oklahoma | 01-Jul-22 | 30-Jun-27 | 449,744.00 |
| You, Dr. Young Jae | Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers | Federal | National Cancer Institute | 13-Jul-22 | 30-Jun-27 | 2,105,595.00 |